Company intelligence / Profile preview

Curevo Vaccine

Bothell, Washington, United Statescurevovaccine.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Curevo’s lead vaccine candidate for shingles has demonstrated excellent immunogenicity and improved tolerability in clinical studies. The company completed a successful Phase I trial showing robust antibody responses with good safety, followed by positive results in later-stage trials. Their approach focuses on non-mRNA adjuvanted subunit vaccines to address issues of tolerability and accessibility seen with current market leaders like Shingrix®.

Therapeutic areas: Infectious Diseases
Modalities: Adjuvanted subunit vaccines (non-mRNA)
Industry: Biotech

Drug pipeline

1 asset

amezosvatein

Partnerships

GC Pharma/GC Biopharma/MOGAM Institute for Biomedical Research – research collaboration partner and founding investorIDRI – initial research collaboration partner

Beyond the preview

Go deeper on Curevo Vaccine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curevo Vaccine.

Explore the full profile